| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T11 |
0-93 |
Sentence |
denotes |
The novel coronavirus, SARS-CoV2, can cause a potentially fatal disease, COVID-19, in humans. |
| T12 |
94-164 |
Sentence |
denotes |
Here, we will provide an overview of therapeutic options for COVID-19. |
| T13 |
165-314 |
Sentence |
denotes |
Plasma from patients recovered from COVID-19 that contains antibodies against SARS-CoV2 has shown promising results in patients with severe COVID-19. |
| T14 |
315-406 |
Sentence |
denotes |
Also, IVIG, combined with moderate-dose of corticosteroids, might improve patient outcomes. |
| T15 |
407-467 |
Sentence |
denotes |
Evidence links COVID-19 to variable degrees of inflammation. |
| T16 |
468-553 |
Sentence |
denotes |
Studies show that the use of corticosteroids might accelerate recovery from COVID-19. |
| T17 |
554-683 |
Sentence |
denotes |
There are, however, no controlled clinical trials that show whether the use of corticosteroids can reduce COVID-19-related death. |
| T18 |
684-859 |
Sentence |
denotes |
Also, the pro-inflammatory cytokine IL6 is the best-documented cytokine in COVID-19 correlated with severity, criticality, viral load, and prognosis of patients with COVID-19. |
| T19 |
860-971 |
Sentence |
denotes |
Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. |
| T20 |
972-1154 |
Sentence |
denotes |
Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy. |
